COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,051 Articles (22,627 medRxiv, 8,424 bioRxiv)

Most recent first Previous |  Page 2117: Articles 21161-21170  | Next

Risk Factors Associated with Increased Antibiotic Use in COVID-19 Hospitalized Patients
Martin, A. J., Pillinger, K. E., Shulder, S., Quartuccio, K., Dobrzynski, D.
10.1101/2020.10.21.20217117 — Posted: 2020-10-25
The papain-like protease of coronaviruses cleaves ULK1 to disrupt host autophagy
Mohamud, Y., Chao Xue, Y., Liu, H., Seng Ng, C., Bahreyni, A., Jan, E., Luo, H.
10.1101/2020.10.23.353219 — Posted: 2020-10-25
Evidence for ZAP-independent CpG reduction in SARS-CoV-2 genome, and pangolin coronavirus origin of 5'UTR
Afrasiabi, A., Alinejad-Rokny, H., Lovell, N., Xu, Z., Ebrahimi, D.
10.1101/2020.10.23.351353 — Posted: 2020-10-24
SARS-CoV-2 RBD mutations, ACE2 genetic polymorphism, and stability of the virus-receptor complex: The COVID-19 host-pathogen nexus.
Ashoor, D., Ben Khalaf, N., Marzouq, M., Jarjanazi, H., Fathallah, M. D.
10.1101/2020.10.23.352344 — Posted: 2020-10-24
Ivermectin repurposing for COVID-19 therapy: Safety and pharmacokinetic assessment of a novel nasal spray formulation in a pig model
Errecalde, J., Lifschitz, A., Vecchioli, G., Ceballos, L., Errecalde, F., Ballent, M., Marin, G., Daniele, M., Turic, E., Spitzer, E., Toneguzzo, F., Gold, S., Krolewiecki, A., Alvarez, L., Lanusse, C.
10.1101/2020.10.23.352831 — Posted: 2020-10-24
A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells
Mellott, D., Tseng, C.-T., Drelich, A., Fajtova, P., Chenna, B. C., Kostomiris, D., Hsu, J. C., Zhu, J., Taylor, Z., Tat, V., Katzfuss, A., Li, L., Giardini, M. A., Skinner, D., Hirata, K., Beck, S., Carlin, A. F., Clark, A. E., Berreta, L., Maneval, D., Frueh, F., Hurst, B. L., Wang, H., Kocurek, K. I., Raushel, F. M., O'Donoghue, A., Siqueira-Neto, J. L., Meek, T. D., McKerrow, J. H.
10.1101/2020.10.23.347534 — Posted: 2020-10-24
Single-cell analyses reveal SARS-CoV-2 interference with intrinsic immune response in the human gut
Triana, S., Metz Zumaran, C., Ramirez, C., Kee, C., Doldan, P., Shahraz, M., Schraivogel, D., Gschwind, A. R., Steinmetz, L. M., Herrmann, C., Alexandrov, T., Boulant, S., Stanifer, M. L.
10.1101/2020.10.21.348854 — Posted: 2020-10-24
Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19
Le, B. L., Andreoletti, G., Oskotsky, T., Vallejo-Gracia, A., Rosales, R., Yu, K. Z., Kosti, I., Leon, K. E., Bunis, D. G., Li, C., Kumar, G. R., White, K. M., Garcia-Sastre, A. E., Ott, M., Sirota, M.
10.1101/2020.10.23.352666 — Posted: 2020-10-23
Simulation and prediction of further spread of COVID-19 in The Republic of Serbia by SEIRDS model of disease transmission
Stanojevic, S. G., Ponjavic, M., Stanojevic, S., Stevanovic, A., Radojicic, S.
10.1101/2020.10.21.20216986 — Posted: 2020-10-23
The effect of COVID-19 on critical care research: A prospective longitudinal multinational survey
Duffett, M., Cook, D. J., Strong, G., Lee, J. H., Kho, M. E.
10.1101/2020.10.21.20216945 — Posted: 2020-10-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).